protocolSection identificationModule nctId: NCT06352073, orgStudyIdInfo id: 23-2625, secondaryIdInfos id: R668-EE-2380, type: OTHER, domain: Regeneron, briefTitle: Dupilumab for Eosinophilic Esophagitis With Severe Strictures, acronym: DESTRICT, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-11, completionDateStruct date: 2026-04, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: University of North Carolina, Chapel Hill, class: OTHER, collaborators name: Regeneron Pharmaceuticals, collaborators name: Sanofi, descriptionModule briefSummary: The purpose of this research study is to determine how well an FDA-approved drug, dupilumab, works to treat patients with severe strictures and active Eosinophilic Esophagitis (EoE). This is an open-label study, meaning everyone in the study will receive dupilumab.Participants will have a screening visit where they will complete surveys and undergo an endoscopy (EGD). Blood and biopsies (small tissue samples) will also be collected. If eligible and enrolled into the study, participants will receive weekly subcutaneous (under the skin) injections of dupilumab for 52 weeks (one year). The first dose of dupilumab will be administered at the week 1 visit by a clinician and participants will receive training on how to self-administer the remaining doses.Participants will return for study visits every at weeks 4, 8, 12, 18, 24, 30, 36, 44, and 52. During these visits, vital signs (temperature, heart rate, etc.) will be collected and participants will complete surveys. During visits at week 12, 24, and 52, blood will be collected and an endoscopy with biopsy will be performed.At 64 weeks (12 weeks after the last dose of dupilumab), participants assigned male at birth (AMAB) will be contacted about their / their partner's pregnancy status and participants assigned female at birth (AFAB) may be asked to come for an in-person visit to complete a urine pregnancy test., conditionsModule conditions: Eosinophilic Esophagitis, conditions: EoE, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Dupilumab, outcomesModule primaryOutcomes measure: Histologic Response to Dupilumab, secondaryOutcomes measure: Change in Minimum Esophageal Caliber, secondaryOutcomes measure: Decrease in Number of Dilations, secondaryOutcomes measure: Change in Endoscopic Severity, secondaryOutcomes measure: Change in Histologic Severity, eligibilityModule sex: ALL, minimumAge: 16 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of North Carolina at Chapel Hill, city: Chapel Hill, state: North Carolina, zip: 27599, country: United States, contacts name: Julia Phillips, role: CONTACT, phone: 919-843-4453, email: julia_phillips@med.unc.edu, contacts name: Hiwot Ekuban, role: CONTACT, email: hiwot_ekuban@med.unc.edu, geoPoint lat: 35.9132, lon: -79.05584, hasResults: False